سعر سونينيفيل 50 مجم 28 كبسولة 2026

Suninevel sunitinib 50 mg hard capsules, pack of 28 (Hikma Specialized Pharmaceuticals, Egypt); oral multi-kinase inhibitor antineoplastic.

• Gastrointestinal stromal tumour (GIST) after disease progression on or intolerance to imatinib (adults).DailyMed (U.S. National Library of Medicine)
• Advanced renal cell carcinoma (adults).DailyMed (U.S. National Library of Medicine)
• Adjuvant treatment of adults at high risk of recurrent renal cell carcinoma following nephrectomy.DailyMed (U.S. National Library of Medicine)

• Most common (>=25%): fatigue/asthenia, diarrhoea, mucositis/stomatitis, nausea, decreased appetite, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia, dyspepsia and thrombocytopenia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• The US label lists no contraindications.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: hepatotoxicity may be severe and in some cases fatal; monitor liver function tests at baseline, during each cycle and as clinically indicated; interrupt, reduce or discontinue as recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Cardiovascular events including myocardial ischaemia/infarction, heart failure, cardiomyopathy and decreased LVEF; QT prolongation and torsade de pointes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypertension; haemorrhagic events (including tumour-related haemorrhage and viscus perforation); tumour lysis syndrome; thrombotic microangiopathy; proteinuria/nephrotic syndrome.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitorsMay increase sunitinib concentrations; choose an alternative or consider dose reduction.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersMay decrease sunitinib concentrations; choose an alternative or consider dose increase.DailyMed (U.S. National Library of Medicine)
• QT-prolonging drugsMonitor QT interval with ECGs more frequently.DailyMed (U.S. National Library of Medicine)

• Based on animal data and mechanism of action, sunitinib can cause fetal harm; no human data.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment and for at least 4 weeks after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)